However, the company said the results below the operating EBIT line were not directly comparable to figures outlined in the prospectus because those included "non-operating entities that formed part of the IPO structure" such as shareholder loans. "The shareholder loans were repaid in conjunction with the IPO in July 2014," the company said. "As such, the related finance costs and tax impact arising from these finance costs are not considered relevant to the future operation of the business.
Operating EBITDA adds back tax and finance costs as well as $31. 7 million in costs related to the initial public offering. The net loss of $19. 3 million was far lower than the loss of $145. 1 million outlined in the forecasts in Healthscope’s share sale documents.
Read more here: SMH